TERN חוב כולל להון Terns Corp

Terns Pharmaceuticals (TERN) relies on the development of the oral obesity drug TERN-601 and a substantial cash reserve. The history of changes in the total debt-to-equity ratio confirms financial stability, where 0.00 captures the magnitude of this parameter. However, geopolitics complicates raw material logistics and testing, while environmental risks are limited solely by the strict disposal of hazardous waste.

The total debt-to-equity ratio determines the extent of a business's reliance on external borrowings relative to its own funds. This metric is calculated as the sum of all liabilities divided by shareholders' equity, reflecting the stability of the balance sheet. By analyzing this chart of the debt-to-equity ratio, an investor assesses the risk of cash flow gaps amid rising interest rates. The low leverage of Terns Pharmaceuticals (TERN) is critically important for financing patent development, which will ensure high margins for future sales of blockbuster drugs.